Long-term suppression with oral acyclovir of recurrent herpes simplex virus infections in otherwise healthy patients. A European multicenter study.
In a multicenter study, the efficacy of oral acyclovir 800 mg daily in preventing the development of recurrent herpes simplex virus lesions in 379 patients was assessed. Medication given in two or four divided doses daily for one year was highly effective and well tolerated. A high therapeutic index of acyclovir was maintained throughout the period of study.
D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005060:Europe; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012008:Recurrence; D013997:Time Factors
D000212:Acyclovir